Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

ARNA 4.12 -0.02 (-0.48%)
price chart
Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically, Arena Pharmaceuticals' (NASDAQ: ARNA ) Belviq and VIVUS's (NASDAQ: VVUS ) Qsymia reported a combined 283,000 prescriptions ...
Arena And Vivus Investors Need To Watch Orexigen  Seeking Alpha (registration)
Related articles »  
Arena Pharmaceuticals, Inc. Earnings: Looking for More
Most biotech investor would be happy with 30% quarter-over-quarter prescription growth in a market that didn't grow much. But for Arena Pharmaceuticals' (NASDAQ: ARNA ) Belviq, the growth is coming off such a small base that it's hard to get too excited.
Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows  Zacks.com
Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 ...  MarketWatch
Related articles »  
Arena Pharmaceuticals, Inc., Loews Corporation, and Sysco Corporation ...
As Capitol Hill keeps its eyes closely trained on November elections, Wall Street's attention is elsewhere as earnings season continues this week.
Related articles »  
Why Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is Rising?
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) surged as much as 6.6%. It was a welcome reprieve for Arena shareholders, who had seen the stock lose 25% of its value this year before today's gains.
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?  Zacks.com
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue? - Tale of ...  Nasdaq
Related articles »  
Arena Pharmaceuticals Issued Composition of Matter Patent by United States ...
25, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the US Patent and Trademark Office granted Arena U.S.
Arena Pharma granted patent for pulmonary hypertension drug  San Diego Source (subscription)
Related articles »  
Morning Stock Alert: Arena Pharmaceuticals, Inc. (ARNA), Occidental Petroleum ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) of the Healthcare sector has a change from open of - 0.240% since the opening bell today with a volume of 334,007 shares.
Related articles »  
Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare ...
24, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ARNA, -0.72% announced today that the company is scheduled to present a corporate overview and update at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014, ...
Belviq And Smoking Cessation - Clearing The Air
When Arena Pharmaceuticals (NASDAQ:ARNA) announced that a trial for Belviq as a smoking cessation product was being enrolled, I saw opportunity.
Related articles »  
Stocks to watch: InvenSense, Inc. (INVN), Arena Pharmaceuticals, Inc. (ARNA)
In the Technology sector (Semiconductor - Integrated Circuits), InvenSense, Inc. (INVN) saw a loss of -3.84%, It was a change from open of- 5.24% at the close of the trading day with a volume of 2,415,441 shares.
Technical Updates on Biotech Stocks - ImmunoGen, Lexicon Pharma ...
Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. IMGN, +1.65% Lexicon Pharmaceuticals Inc. LXRX, -5.47% ZIOPHARM Oncology Inc. ZIOP, +4.04% Arena Pharmaceuticals Inc. ARNA, -0.24% and Regulus Therapeutics Inc.
Related articles »